Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADA16 hydrogel versus oxidised regenerated cellulose for bleeding control after endoscopic turbinate surgery
ACTRN12620001266954Phase 4Not yet recruiting
- Sponsor
- RPA Institute of Academic Surgery
- Start
- Jan 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of RADA16 in nasal congestion (2 arms), sponsored by RPA Institute of Academic Surgery. Primary endpoint: Bleeding events in first 24 hours post-operatively. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
RADA16
03
Conditions
nasal congestion
Beyond the preview
Go deeper on ACTRN12620001266954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001266954.